Tris Pharma Inc Drug Patent Portfolio
Tris Pharma Inc owns 7 orange book drugs protected by 12 US patents with Onyda Xr having the least patent protection, holding only 2 patents. And Dyanavel Xr with maximum patent protection, holding 7 patents. Given below is the list of Tris Pharma Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11918689 | Liquid clonidine extended release composition | 28 Jul, 2041 | Active |
US11590081 | Extended release amphetamine tablets | 24 Sep, 2038 | Active |
US11590228 | Extended release amphetamine compositions | 07 Sep, 2036 | Active |
US8062667 | Modified release formulations containing drug-ion exchange resin complexes | 29 Mar, 2029 | Active |
US10086087 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
US8597684 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
US8747902 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
US8883217 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
US9675703 | Modified release formulations containing drug - ion exchange resin complexes | 15 Mar, 2027 | Active |
US8337890 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
US9675704 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
US8790700 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
Latest Legal Activities on Tris Pharma Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tris Pharma Inc.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8337890 |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8337890 |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8337890 |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8337890 |
Post Issue Communication - Certificate of Correction | 06 Nov, 2023 | US11590228 |
Email Notification
Critical
| 29 Sep, 2023 | US11590228 |
Mail Pub Notice re 312 amendment | 29 Sep, 2023 | US11590228 |
Post Issue Communication - Certificate of Correction Denied | 27 Sep, 2023 | US11590228 |
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 26 Sep, 2023 | US11590228 |
Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2023 | US8062667 (Litigated) |
Patent Issue Date Used in PTA Calculation
Critical
| 28 Feb, 2023 | US11590228 |
Patent Issue Date Used in PTA Calculation
Critical
| 28 Feb, 2023 | US11590081 |
Recordation of Patent Grant Mailed
Critical
| 28 Feb, 2023 | US11590081 |
Recordation of Patent Grant Mailed
Critical
| 28 Feb, 2023 | US11590081 |
Recordation of Patent Grant Mailed
Critical
| 28 Feb, 2023 | US11590228 |
Tris Pharma Inc's Family Patents
Tris Pharma Inc Drug List
Given below is the complete list of Tris Pharma Inc's drugs and the patents protecting them.
1. Dyanavel Xr
Dyanavel Xr is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11590228 | Extended release amphetamine compositions |
07 Sep, 2036
(11 years from now)
| Active |
US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
29 Mar, 2029
(4 years from now)
| Active |
US10086087 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8597684 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8747902 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8883217 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US9675703 | Modified release formulations containing drug - ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr's drug page
2. Dyanavel Xr 10
Dyanavel Xr 10 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11590081 | Extended release amphetamine tablets |
24 Sep, 2038
(13 years from now)
| Active |
US8337890 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8747902 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US9675704 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 10's drug page
3. Dyanavel Xr 15
Dyanavel Xr 15 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11590081 | Extended release amphetamine tablets |
24 Sep, 2038
(13 years from now)
| Active |
US8337890 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8747902 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US9675704 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 15's drug page
4. Dyanavel Xr 20
Dyanavel Xr 20 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11590081 | Extended release amphetamine tablets |
24 Sep, 2038
(13 years from now)
| Active |
US8337890 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8747902 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US9675704 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 20's drug page
5. Dyanavel Xr 5
Dyanavel Xr 5 is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11590081 | Extended release amphetamine tablets |
24 Sep, 2038
(13 years from now)
| Active |
US8337890 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US8747902 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
US9675704 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dyanavel Xr 5's drug page
Explore Our Curated Drug Screens
6. Onyda Xr
Onyda Xr is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11918689 | Liquid clonidine extended release composition |
28 Jul, 2041
(16 years from now)
| Active |
US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
29 Mar, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onyda Xr's drug page
7. Tuzistra Xr
Tuzistra Xr is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
29 Mar, 2029
(4 years from now)
| Active |
US8790700 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tuzistra Xr's drug page